The peptide SS-31 reversed mitochondrial damage and reduced brain swelling, cell death, and neurological deficits when given 30 minutes after traumatic brain injury in mice.
Mitochondria restoredSS-31 reversed mitochondrial dysfunction and promoted new mitochondria creation via SIRT1/PGC-1α pathway after TBI
What the researchers found
The mitochondria-targeted peptide SS-31 (elamipretide) provided significant neuroprotection after traumatic brain injury in mice when administered 30 minutes post-injury. SS-31 reversed mitochondrial dysfunction by reducing reactive oxygen species, restoring superoxide dismutase activity, decreasing oxidative damage markers (MDA), and preventing cytochrome c release.
This translated to reduced neurological deficits, brain swelling, DNA damage, and neural cell death. Mechanistically, SS-31 restored SIRT1 expression and promoted PGC-1α nuclear translocation, suggesting it enhanced mitochondrial biogenesis — the creation of new, healthy mitochondria to replace damaged ones.
Why it matters
Traumatic brain injury is a leading cause of death and disability with no approved neuroprotective drugs. SS-31's ability to rapidly restore mitochondrial function after injury addresses a critical therapeutic gap. If these findings translate to humans, this peptide could be administered in emergency settings to limit the secondary brain damage that follows the initial injury.
The numbers in context
5 mg/kg SS-31 · IP injection 30 min post-TBI · 24-hour endpoint · Reduced ROS, MDA, cytochrome c · Restored SOD, SIRT1, PGC-1α · Decreased brain edema and apoptosis
How the study worked
Mouse study using a modified Marmarou weight-drop model of traumatic brain injury. Mice were randomized to sham, TBI, TBI+vehicle, or TBI+SS-31 (5 mg/kg IP, 30 min post-injury). Brain tissue was harvested at 24 hours for analysis of mitochondrial function markers, oxidative stress (ROS, SOD, MDA), cytochrome c release, SIRT1/PGC-1α expression (Western blot, immunohistochemistry), brain water content, DNA damage, and neuronal apoptosis.
Who was studied
Male mice with experimentally induced traumatic brain injury
What this study cannot tell us
Single-dose, single-timepoint mouse study with assessment at only 24 hours post-injury. Long-term neurological outcomes and dose-response relationships were not evaluated. The weight-drop TBI model has limitations in replicating the heterogeneity of human brain injuries. Translation from mouse to human TBI has historically been challenging.
How to read the evidence
This is a single-species, single-timepoint animal study. While the results are comprehensive and mechanistically detailed, TBI neuroprotection has notoriously failed to translate from animal models to human trials, warranting caution.
When this study was published
Published in 2018, this study is part of ongoing preclinical research into SS-31/elamipretide. The peptide continues to be investigated in clinical trials for mitochondrial diseases and cardiac conditions.
The bigger picture
SS-31 (also known as elamipretide or Bendavia) is being studied for multiple conditions involving mitochondrial dysfunction, including heart failure and rare mitochondrial diseases. This study extends its potential to traumatic brain injury, a condition affecting millions annually with no approved neuroprotective treatment. The SIRT1/PGC-1α pathway activation suggests SS-31 doesn't just protect existing mitochondria but promotes mitochondrial renewal.
Questions still open
- Does SS-31 provide neuroprotection when administered hours rather than minutes after TBI?
- Would repeated SS-31 dosing improve long-term neurological recovery beyond the 24-hour endpoint?
- Is the SIRT1/PGC-1α pathway essential for SS-31's neuroprotective effect, or is ROS scavenging sufficient?
Common questions
What is SS-31 and how does it work?
Why is mitochondrial dysfunction important in brain injuries?
Read the original research
SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury.
Oxidative medicine and cellular longevity, 2018, 4783602
Citation
Zhu, Yihao; Wang, Handong; Fang, Jiang; Dai, Wei; Zhou, Jiang; Wang, Xiaoliang; Zhou, Mengliang. (2018). SS-31 Provides Neuroprotection by Reversing Mitochondrial Dysfunction after Traumatic Brain Injury.. Oxidative medicine and cellular longevity, 2018, 4783602. https://doi.org/10.1155/2018/4783602